Purpose

The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)

Conditions

Eligibility

Eligible Ages
Between 1 Year and 17 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • New diagnosis of de novo ALL, lymphomas (T or B cell), or mixed-phenotype acute leukemia - Planned 3-4 drug systemic induction chemotherapy with a corticosteroid, vincristine and a single dose or multiple doses of asparaginase, with or without daunorubicin - Functioning Central Venous Access Device - Must be able to tolerate oral medication or have it administered via an Nasogastric tube (NGT) or GT tube - Males and females,age 1 year(365 days) to < 18 (17 years and 364 days) years.

Exclusion Criteria

  • Subjects scheduled to have > 3 Lumbar Punctures over the course of the study treatment period - Prior history of documented DVT or PE in the past 3 months - Known inherited bleeding disorder or coagulopathy - Major surgery [excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open biopsy] within the last 7 days prior to enrollment that may be associated with a risk of bleeding. Open biopsy is considered a major surgery. - Uncontrolled severe hypertension at enrollment. Severe hypertension is defined as a systolic or diastolic blood pressure (BP) > 5 mm Hg above the 95th percentile as defined by the National High Blood Pressure Education Program Working Group (NHBPEP) established guidelines for the definition of normal and elevated blood pressure in children - Extreme hyperleukocytosis, white blood cell (WBC) counts over 200 x 109/L (200,000/microL) at the time of enrollment - Liver dysfunction manifested by SGTP (ALT) > 5X Upper limit of normal (ULN) and/or Aspartate aminotransferase (AST) >5 X ULN and/or direct (conjugated) bilirubin > 2X ULN - Renal function < 30% of normal for age and size as determined by the Schwartz formula - International normalized ratio (INR) > 1.4 and activated partial thromboplastin time (aPTT) > 3 seconds above the upper limit of normal for age, within 1 week prior to enrollment. - History of allergy to apixaban or Factor Xa inhibitors - History of significant adverse reaction or major bleeding related adverse reaction to other anticoagulant or antiplatelet agents - History of any significant drug allergy (such as anaphylaxis or hepatotoxicity - Any investigational drug being administered during the study Other protocol inclusion/exclusion criteria may apply

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Prevention
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Apixaban
Children aged 1 to <18 years weighing 6 to <35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days. Children aged 1 to <18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects < 5years and < 35 kg may be administered 0.5-mg tablets only
  • Drug: Apixaban
Placebo Comparator
No systemic anticoagulant prophylaxis
No systemic anticoagulant prophylaxis
  • Other: No systemic anticoagulant prophylaxis

More Details

Status
Completed
Sponsor
Bristol-Myers Squibb

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.